Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension

By afschroeder • May 9, 2026

Osterhout R, Boucly A, Benza RL, Channick RN, Chin KM, Frantz RP, Hemnes AR, Howard LS, Mclaughlin VV, Sitbon O, Vachiéry JL, Zamanian RT, Aranda R, Cravets M, Ding Z, Duong-Verlé T, Mottola D, Roscigno RF, Sitapara R, Zisman LS, Bruey JM, Ghofrani HA. Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2026 May 8:aamag175. doi: 10.1093/ajrccm/aamag175. Epub ahead of print. PMID: 42104009.

Tags: Hemodynamics, Inflammation Mediators, Molecular Mechanisms of Pharmacological Action, Publications, Pulmonary, Critical Care & Sleep Medicine, Tyrosine kinase inhibitor, Vascular remodeling

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. Reply

Rana AI, Castillo-Mancilla J, Landovitz RJ. Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. Reply. N Engl J Med. 2026 May 14;394(19):1963-1964. doi:[...]

Prevalence, Progression, and Prognosis of Heart Stress In the Community: Implications for Heart Failure Prevention

Cai A, Liu L, Feng Y, Zhou Y, Li L, Bozkurt B, Januzzi JL, Lam CSP, Fonarow GC, Pandey A, Zhou Z, Cheng Y, Bayes-Genis[...]

Improved Assessment of Coronary Artery Disease in Obese Subjects with Flurpiridaz-18F PET Myocardial Perfusion Imaging: A Prespecified Subgroup Analysis of the AURORA Phase 3 Study

Patel KK, Maddahi J, Agostini D, Bax JJ, Beanlands RSB, Berman D, Dorbala S, Heller GV, Knuuti JM, Pelletier-Galarneau M, Tamaki N, Thompson D, Somer[...]